At Cerveau Technologies we’re working towards the vision of globally developing diagnostics and technology in partnership with Enigma Biomedical Group and Sinotau Pharmaceutical Group. In turn, these developments can have a profoundly positive impact on patients suffering from neurodegenerative disorders, like Alzheimer’s disease.
On June 22, Cerveau Technologies has signed an exciting agreement, one with the Kobe City Hospital Organization in Japan. This partnership will support multiple projects over the next coming years focused on manufacturing and supplying the [18F]MK-6240 needed for initiatives located in the Kansai area.
The research projects will explore studies entered around the early stage imaging agent (MK-6420) and how this can be utilized in Positron Emission Tomography (PET) scans in order to assess and analyze the status and progression of the neurofibrillary tangles (NFTs) in the brain.
These NFTs are the most commonly known markers of neurodegenerative diseases like Alzheimer’s, made up of abnormal accumulations of a protein called tau.
Dr. Michio Senda, MD, PhD, Director of Molecular Imaging at Kobe City Medical Center General Hospital (KCGH), which is managed by Kobe City Hospital Organization (KCHO), stated “Tau-PET imaging is an excellent tool of visualizing and evaluating neurofibrillary tangles in the living human brain affected by Alzheimer’s disease, tauopathies, or other brain disorders. It is also valuable for clinical trials of therapeutic drugs for those diseases, which will be facilitated in Japan by the collaboration with Cerveau.”
Together, Cerveau and Kobe city will benefit patients with brain diseases. the collaboration with KCHO will further and support the global production network in Europe, Canada, Japan, China, Singapore, Australia and the United States.